Medicines Position Statements – NEL NEL LPP and London Diabetes Network joint statement: Access to continuous glucose monitors for adults living with type 2 diabetes in London IQoro® position statement for hiatus hernia and reflux, stroke-related dysphagia and other indications (NEL)_02.2024 Position statement: GLP-1 analogues: Semaglutide (Wegovy®) and Liraglutide (Saxenda®) for managing overweight and obesity – Sept 24 Position statement on generic and brand prescribing (NEL) Preferred DOAC prescribing position statement (NEL)_04.2024